Adult T cell leukemia/lymphoma (ATL)

研究成果: Review article

抄録

Adult T cell leukemia/lymphoma(ATL) is an aggressive, fatal malignancy associated with human T-lymphotropic virus type I(HTLV-I). The median survival time of acute- and lymphoma-type ATL is 6 and 10 months, respectively. According to recent reports, nearly half of the ATL patients who received allogeneic hematopoietic stem cell transplantation could survive without disease for over 3 years. However, the population of patients who are eligible for conventional transplantation is extremely limited. Therefore, a reduced-intensity allogeneic stem cell transplantation(RIST) is applied to ATL patients and a multi-center phase I clinical trial is now underway. In our institute, 5 patients, who received RIST, are all alive, with 1 case relapsed after 6 months. Thus, RIST is considered very promising.

元の言語English
ページ(範囲)1592-1595
ページ数4
ジャーナルNippon rinsho. Japanese journal of clinical medicine
61
発行部数9
出版物ステータスPublished - 2003
外部発表Yes

Fingerprint

Adult T Cell Leukemia Lymphoma
Stem Cell Transplantation
Clinical Trials, Phase I
Hematopoietic Stem Cell Transplantation
Lymphoma
Transplantation
Viruses
Survival
Population
Neoplasms

これを引用

Adult T cell leukemia/lymphoma (ATL). / Tanosaki, Ryuji.

:: Nippon rinsho. Japanese journal of clinical medicine, 巻 61, 番号 9, 2003, p. 1592-1595.

研究成果: Review article

@article{5558eca8c42643c6a1a3f41dffd62b70,
title = "Adult T cell leukemia/lymphoma (ATL)",
abstract = "Adult T cell leukemia/lymphoma(ATL) is an aggressive, fatal malignancy associated with human T-lymphotropic virus type I(HTLV-I). The median survival time of acute- and lymphoma-type ATL is 6 and 10 months, respectively. According to recent reports, nearly half of the ATL patients who received allogeneic hematopoietic stem cell transplantation could survive without disease for over 3 years. However, the population of patients who are eligible for conventional transplantation is extremely limited. Therefore, a reduced-intensity allogeneic stem cell transplantation(RIST) is applied to ATL patients and a multi-center phase I clinical trial is now underway. In our institute, 5 patients, who received RIST, are all alive, with 1 case relapsed after 6 months. Thus, RIST is considered very promising.",
author = "Ryuji Tanosaki",
year = "2003",
language = "English",
volume = "61",
pages = "1592--1595",
journal = "Nihon rinsho. Japanese journal of clinical medicine",
issn = "0047-1852",
publisher = "Nipponrinsho Co., Inc.",
number = "9",

}

TY - JOUR

T1 - Adult T cell leukemia/lymphoma (ATL)

AU - Tanosaki, Ryuji

PY - 2003

Y1 - 2003

N2 - Adult T cell leukemia/lymphoma(ATL) is an aggressive, fatal malignancy associated with human T-lymphotropic virus type I(HTLV-I). The median survival time of acute- and lymphoma-type ATL is 6 and 10 months, respectively. According to recent reports, nearly half of the ATL patients who received allogeneic hematopoietic stem cell transplantation could survive without disease for over 3 years. However, the population of patients who are eligible for conventional transplantation is extremely limited. Therefore, a reduced-intensity allogeneic stem cell transplantation(RIST) is applied to ATL patients and a multi-center phase I clinical trial is now underway. In our institute, 5 patients, who received RIST, are all alive, with 1 case relapsed after 6 months. Thus, RIST is considered very promising.

AB - Adult T cell leukemia/lymphoma(ATL) is an aggressive, fatal malignancy associated with human T-lymphotropic virus type I(HTLV-I). The median survival time of acute- and lymphoma-type ATL is 6 and 10 months, respectively. According to recent reports, nearly half of the ATL patients who received allogeneic hematopoietic stem cell transplantation could survive without disease for over 3 years. However, the population of patients who are eligible for conventional transplantation is extremely limited. Therefore, a reduced-intensity allogeneic stem cell transplantation(RIST) is applied to ATL patients and a multi-center phase I clinical trial is now underway. In our institute, 5 patients, who received RIST, are all alive, with 1 case relapsed after 6 months. Thus, RIST is considered very promising.

UR - http://www.scopus.com/inward/record.url?scp=0642371212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0642371212&partnerID=8YFLogxK

M3 - Review article

C2 - 14515729

AN - SCOPUS:0642371212

VL - 61

SP - 1592

EP - 1595

JO - Nihon rinsho. Japanese journal of clinical medicine

JF - Nihon rinsho. Japanese journal of clinical medicine

SN - 0047-1852

IS - 9

ER -